Aurinia Pharmaceuticals I... (AUPH)
NASDAQ: AUPH
· Real-Time Price · USD
12.30
-0.22 (-1.76%)
At close: Sep 17, 2025, 3:59 PM
12.20
-0.81%
After-hours: Sep 17, 2025, 07:38 PM EDT
-1.76% (1D)
| Bid | 12.29 |
| Market Cap | 1.62B |
| Revenue (ttm) | 260.11M |
| Net Income (ttm) | 60.64M |
| EPS (ttm) | 0.43 |
| PE Ratio (ttm) | 28.6 |
| Forward PE | 16.86 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 12.32 |
| Volume | 1,099,901 |
| Avg. Volume (20D) | 2,150,051 |
| Open | 12.63 |
| Previous Close | 12.52 |
| Day's Range | 12.18 - 12.66 |
| 52-Week Range | 6.55 - 12.90 |
| Beta | 1.27 |
| Ex-Dividend Date | n/a |
About AUPH
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AUPH
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AUPH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAurinia Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
10 months ago
+10.9%
Aurinia Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
1 month ago · seekingalpha.com
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)Aurinia Pharmaceuticals Inc. reported total revenues of $70M in Q2 '25, aided by record Lupkynis net product sales of $66.6M. AUPH management continues to execute well, maintaining positive cash flow,...
2 months ago · seekingalpha.com
The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides OpportunityI revisit biopharma name Aurinia Pharmaceuticals Inc. for the first time in 2025 after the company reported solid Q1 results in May. The quarter saw Lupkynis net product revenues up 25% year-over-year...
